For research use only
| Cat No. | ABC-X0245C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphoblast-like |
| Species | Human |
| Host Cell | MOLM-13 |
| Source Organ | Blood |
| Disease | Acute Myeloid Leukemia |
| Storage | Liquid Nitrogen |
The Xpress™ Human AXL over-expressing cell line (MOLM-13) support studies on leukemia, drug resistance, and the AXL signaling pathway in cancer.
AXL MOLM-13 Overexpression Cell Line is a genetically engineered model derived from the MOLM-13 acute myeloid leukemia cell line, tailored to customer requirements. AXL MOLM-13 overexpression cell line is generated by stable integration of exogenous human AXL into host cells via optimized lentiviral transduction. Overexpression clone is validated at gene level by qRT-PCR.
Target
The AXL gene encodes a receptor tyrosine kinase involved in cell survival, proliferation, and immune modulation via the PI3K/AKT and MAPK pathways. Its overexpression is associated with therapy resistance and poor prognosis in leukemia, non-small cell lung cancer, and breast cancer. AXL is a critical mediator of epithelial-to-mesenchymal transition and immune evasion. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0245C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblast-like |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Blood |
| Disease | Acute Myeloid Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | MOLM-13 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model facilitates studies on AXL-driven oncogenic signaling in myeloid malignancies, offering a tool for evaluating AXL-targeted inhibitors and antibody therapies. It supports drug screening and mechanistic analysis of leukemic cell proliferation and immune checkpoint regulation.